Literature DB >> 19924808

Subepithelial dendritic B cells in orofacial granulomatosis.

Pritash Patel1, Francesca Barone, Carlo Nunes, Laurent Boursier, Edward Odell, Michael Escudier, Stephen Challacombe, Jonathan Brostoff, Jo Spencer, Jeremy Sanderson.   

Abstract

BACKGROUND: Orofacial granulomatosis (OFG) is a chronic, disfiguring, granulomatous inflammation of the lips and oral mucosa. The pathogenesis is unknown, but it has been linked previously to Crohn's disease (CD) and more recently to dietary sensitivity. The oral mucosa is an immunologically responsive site associated with the generation of protective mucosal and systemic immune responses to vaccination and also hyperresponsiveness to allergens in some individuals. Classically, immune responses in oral mucosa are considered to be mediated by mucosa-associated lymphoid tissues (MALT), secondary lymphoid follicles that are intimately associated with epithelia.
METHODS: Immunohistochemistry was used to investigate the inflammatory infiltrate in OFG and control tissue samples. Polymerase chain reaction (PCR), cloning of PCR products, and sequencing were used to characterize the local immunoglobulin gene profile in OFG.
RESULTS: We describe large, active, dendritic B cells in oral mucosa that were not associated with any organized lymphoid tissues in the local subepithelial microenvironment. They express activation induced cytidine deaminase, which is essential for immunoglobulin gene diversification by somatic hypermutation and class switch recombination. IgE is also expressed by these B cells. They do not align with any other previously described B-cell subset in secondary lymphoid tissues in terms of morphology, proliferative activity, or phenotype.
CONCLUSIONS: These subepithelial dendritic B cells may contribute to the immune responsiveness of the oral mucosa, including IgE-mediated allergic responses. In patients with OFG, further understanding of the role these cells play in oral immunity may lead to novel therapeutic possibilities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19924808     DOI: 10.1002/ibd.21169

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  The role of exclusive enteral nutrition in the management of orofacial granulomatosis in children.

Authors:  Mohamed Mutalib; Khaled Bezanti; Mamoun Elawad; Fevronia Kiparissi
Journal:  World J Pediatr       Date:  2016-11-03       Impact factor: 2.764

2.  Immunophenotype in orofacial granulomatosis with and without Crohn's disease.

Authors:  Gita Gale; Sofia Ostman; Robert Saalman; Esbjörn Telemo; Mats Jontell; Bengt Hasséus
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-11-01

3.  Genetic Association Analysis Reveals Differences in the Contribution of NOD2 Variants to the Clinical Phenotypes of Orofacial Granulomatosis.

Authors:  Alexander Mentzer; Shalini Nayee; Yasmin Omar; Esther Hullah; Kirstin Taylor; Rishi Goel; Hannah Bye; Tarik Shembesh; Timothy R Elliott; Helen Campbell; Pritash Patel; Anita Nolan; John Mansfield; Stephen Challacombe; Michael Escudier; Christopher G Mathew; Jeremy D Sanderson; Natalie J Prescott
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

4.  Streptococcus Salivarius: A Potential Salivary Biomarker for Orofacial Granulomatosis and Crohn's Disease?

Authors:  Rishi M Goel; Erica M Prosdocimi; Ariella Amar; Yasmin Omar; Michael P Escudier; Jeremy D Sanderson; William G Wade; Natalie J Prescott
Journal:  Inflamm Bowel Dis       Date:  2019-07-17       Impact factor: 5.325

Review 5.  The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers?

Authors:  Khalid Elmaghrawy; Séamus Hussey; Gary P Moran
Journal:  Front Pediatr       Date:  2021-01-21       Impact factor: 3.418

6.  Clinical evidence for allergy in orofacial granulomatosis and inflammatory bowel disease.

Authors:  Pritash Patel; Jonathan Brostoff; Helen Campbell; Rishi M Goel; Kirstin Taylor; Shuvra Ray; Miranda Lomer; Michael Escudier; Stephen Challacombe; Jo Spencer; Jeremy Sanderson
Journal:  Clin Transl Allergy       Date:  2013-08-15       Impact factor: 5.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.